{'fraction_non_alphanumeric': 0.026341463414634145, 'fraction_numerical': 0.015609756097560976, 'mean_word_length': 5.662337662337662, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Blood analyses as prognostic factors in primary lung cancer.

The prognostic value of some pretreatment blood tests was analysed in a follow-up study of 189 patients with non-small cell lung cancer diagnosed in West-Norway between 1976 and 1985. At diagnosis 100 patients had stage III/IV disease. Five-year survival calculated with the life-table method was 12%. In univariate survival analyses significant prognostic factors were stage III/IV disease, weight loss, elevated lactate dehydrogenase, gamma glutamyl transferase, erythrocyte sedimentation rate and alkaline phosphatase, thrombocytosis, leukocytosis and anaemia. In multivariate survival analyses with the Cox's regression model stage III/IV disease, elevated lactate dehydrogenase, thrombocytes and erythrocyte sedimentation rate were significant prognostic factors. It is concluded that these blood analyses at diagnosis in non-small cell lung cancer patients may give additional prognostic information. The need for multivariate analyses is also demonstrated.